Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

Inclusion Criteria: * ICGCT including pure germinoma and MMGCT. * Patients with histologically proven germinoma and MMGCT, including endodermal sinus tumor (yolk sac tumor), embryonal carcinoma, choriocarcinoma and mixed germ cell tumor will be eligible for the study. * Patients with mature/immature teratoma who have tumor marker elevations are eligible on this study. * Patient with ONLY mature and/or immature teratoma are ineligible in the absence of the tumor marker elevations. Exclusion Criteria: * Patients with ICGCTs who are newly diagnosed are excluded from the study. * Patients with the diagnosis of mature or immature teratoma in the absence of tumor marker elevations are excluded from the study. * Patients who are pregnant or breastfeeding are excluded from the study. * Patients who have received previously a high dose chemotherapy regimen and autologous transplant are excluded from this study. * Patients who have received gemcitabine, oxaliplatin and/or paclitaxel are excluded from this study.